39 Results for "

humanized tumor model

" in MedChemExpress (MCE) Product Catalog:
Products (39)

39 Results for "humanized tumor model" in MCE Product Catalog:

Cat. No.: HY-150233
CAS No.: 1160590-05-5
Purity:  99.91%
Target:  

Microtubule/Tubulin

Research Areas:  

Cancer

Cys-McMMAF is the released payload of AlMcMMAF, an anti-5T4 humanized A1 antibody conjugated to the microtubule disrupting MMAF (HY-15579) via a maleimidocaproyl linker. Cys-McMMAF has antitumor efficacy in two tumor mouse models (H1975 and MDA-MB-361-DYT2 models) .
loading...
    loading...
Cat. No.: HY-P99849
CAS No.: 1471999-69-5
Synonyms: ABT-806

Target:  

EGFR

Research Areas:  

Cancer

Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .
loading...
    loading...
Cat. No.: HY-P99101
CAS No.: 2490556-50-6
Synonyms: AEX-4089; MGC026 antibody

Target:  

ADC Antibodies

Research Areas:  

Cancer

Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .
loading...
    loading...
Cat. No.: HY-P99697
CAS No.: 674782-26-4
Synonyms: PRO 140

Target:  

CCR HIV

Research Areas:  

Infection Cancer

Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .
loading...
    loading...
Cat. No.: HY-P991558
Synonyms: RG-7356

Research Areas:  

Cancer

RO-5429083 (RG-7356) is a humanized monoclonal antibody targeting CD44. RO-5429083 binds to the extracellular domain of CD44 and inhibits constitutive EGFR phosphorylation. RO-5429083 suppresses tumor growth in xenograft models and can be used in research related to head and neck squamous cell carcinoma and acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-P991584

Target:  

FGFR

Research Areas:  

Cancer

HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonal antibody. HuGAL-FR21 can block the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibit FGF-induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of FGFR2 in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer .
loading...
    loading...
Cat. No.: HY-142221
CAS No.: 2368182-63-0
Purity:  99.85%
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

ARB-272572 is an oral effective small molecule PD-L1 inhibitor, with an IC50 value of 400 pM. ARB-272572 has research significance in tumors and chronic viral infections .
loading...
    loading...
Cat. No.: HY-P99744
CAS No.: 2254522-19-3
Synonyms: TAK-573

Target:  

CD38

Research Areas:  

Inflammation/Immunology Cancer

Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
loading...
    loading...
Cat. No.: HY-P991570
CAS No.: 2378046-35-4
Synonyms: AD5-10; oba-01 Antibody

Research Areas:  

Cancer

Zaptuzumab (AD5-10) is a DR5-specific humanized monoclonal antibody that selectively binds to DR5 with high affinity. Zaptuzumab specifically induces cancer cell death by both caspase-apoptosis and autophagic cell death (ACD). Zaptuzumab activates both ADCC and CDC. Zaptuzumab induces ROS generation and GSH level reduction. Zaptuzumab shows a significant suppression of the tumor growth and good safety in various xenografts mice tumor models .
loading...
    loading...
Cat. No.: HY-P991444

Target:  

NTPDase ATP Synthase

Research Areas:  

Inflammation/Immunology Cancer

IPH5201 is a selective CD39 inhibitor and a humanized IgG1 monoclonal antibody. IPH5201 selectively binds to and inhibits the enzymatic activity of both membrane-bound and soluble CD39, blocking ATP hydrolysis. IPH5201 enhances the phenotypic maturation and activation of dendritic cells and macrophages. IPH5201 potentiates the anti-tumor effect of Oxaliplatin (HY-17371). IPH5201 shows preliminary evidence of disease stabilization in advanced solid tumor models when used as a single agent or in combination with Durvalumab (HY-P9919). IPH5201 can be used for the research of advanced solid tumors .
loading...
    loading...
Cat. No.: HY-145774
CAS No.: 2597056-04-5
Purity:  99.98%
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice .
loading...
    loading...
Cat. No.: HY-P99809
CAS No.: 2254059-25-9
Synonyms: MK-1308

Target:  

CTLA-4

Research Areas:  

Cancer

Quavonlimab (MK-1308) is a humanized IgG1 monoclonal antibody targeting CTLA-4. As a competitive inhibitor of CTLA-4, Quavonlimab blocks the binding of CTLA-4 to its ligands CD80 and CD86. Quavonlimab increases interferon production, expands and activates T cells, reduces tumor regulatory T cells, inhibits tumor growth, and induces the proliferation of Ki67-positive CD4 and CD8 cells. Quavonlimab can be used in studies related to solid tumors .
loading...
    loading...
Cat. No.: HY-171572
Atezolizumab-MMAE is an anti-PD-L1 antibody-drug conjugate (ADC) with an EC50 of 1.1 nM. Atezolizumab-MMAE is composed of a humanized anti-PD-L1 antibody (Atezolizumab) (HY-P9904), a lysosomally cleavable dipeptide linker (valine-citrulline), a tubulin inhibitor (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Atezolizumab-MMAE has a potent cytotoxicity (EC50: 9.75-11.94 nM) and immune activation effect. Atezolizumab-MMAE has a significantly anti-tumor activity in MC38 xenograft PD-1-humanized immune system mice model .
loading...
    loading...
Cat. No.: HY-P99712
CAS No.: 2362015-67-4
Synonyms: hz208F2-4

Research Areas:  

Cancer

Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye diseases .
loading...
    loading...
Cat. No.: HY-P991230
Target:  

Others

Research Areas:  

Cancer

MK-4830 is a fully humanized monoclonal antibody of the immunoglobulin G4 subclass that specifically binds to ILT4 and blocks its interaction with HLA-G and other ligands. MK-4830 inhibits tumor growth in humanized mouse cancer models .
loading...
    loading...
Cat. No.: HY-P991646
Synonyms: heMab

Research Areas:  

Cancer

ING-1 (heMab) is a high-affinity humanized monoclonal antibody against epithelial cell adhesion molecule (Ep-CAM). ING-1 is a transmembrane glycoprotein mediating Ca 2+. ING-1 binds to Ep-CAM on tumor cells and exhibits potent in vitro activity, targeting and inhibiting tumor growth and metastasis in mouse cancer models. ING-1 is useful in the research of breast, colorectal, and lung cancers, among other cancers .
loading...
    loading...
Cat. No.: HY-P991609
CAS No.: 561063-60-3

Target:  

MMP

Research Areas:  

Cancer

ABX-MA1 is a humanized IgG2 monoclonal antibody inhibitor targeting MCAM/MUC18. ABX-MA1 significantly decreases homotypic aggregation and heterotypic adhesion to HUVECs, and the formation of experimental lung metastasis. ABX-MA1 potently inhibits tumor growth, angiogenesis, and MMP-2 expression in A375SM/WM2664 xenograft mice model, promising for melanoma research .
loading...
    loading...
Cat. No.: HY-P991561
CAS No.: 2691109-74-5

Target:  

CD47

Research Areas:  

Cancer

AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
loading...
    loading...
Cat. No.: HY-P991566
CAS No.: 2983061-18-1

Target:  

CTLA-4

Research Areas:  

Cancer

KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .
loading...
    loading...
Cat. No.: HY-177414
BB-1701 is an anti-HER2 antibody-drug conjugate (ADC). BB-1701 consists of a humanized anti-HER2 antibody (Trastuzumab) (HY-P9907), a linker (Mal-PEG2-VCP), and a microtubule inhibitor (Eribulin) (HY-13442), with the drug-linker conjugate of the ADC being Mal-PEG2-VCP-Eribulin (HY-128870). BB-1701 exhibits potent cytotoxicity against various cancer cells, shows a remarkable bystander effect, and induces immunogenic cell death (upregulated cell surface expression of calreticulin, release of ATP/HMGB1, macrophage infiltration) and apoptosis. BB-1701 potently inhibits tumor growth in T-DM1/T-DXd-resistant tumor models. BB-1701 can be used in studies related to breast cancer, gastric cancer, non-small cell lung cancer, and heterogeneous mixed tumors .
loading...
    loading...